Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults-Reference-Cited by-同舟云学术

Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults

Published:2023-05-09 Issue:5 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Stoniute Akvile¹,Madhuvrata Priya²,Still Madeleine¹,Barron-Millar Evelyn¹,Nabi Ghulam³,Omar Muhammad Imran⁴⁵

Affiliation:

1. Evidence Synthesis Group, Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK

2. Obstetrics & Gynaecology; Sheffield Teaching Hospital NHS Foundation Trust; Sheffield UK

3. Section of Academic Urology, Division of Cancer Research; University of Dundee; Dundee UK

4. Guidelines Office; European Association of Urology; Arnhem Netherlands

5. Academic Urology Unit; University of Aberdeen; Aberdeen UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference676 articles.

1. Abrams P Jackson S Mattiasson A Krishnan K Haendler L A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (Abstract) International Continence Society 26th Annual Meeting; 1996 Aug 27-30; Athens, Greece 1996 276 7

2. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder;Abrams;British Journal of Urology,1998

3. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract);Abrams;Journal of Urology,1997

4. Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO) (Abstract);Abrams;Neurourology and Urodynamics,2001

5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY);Abrams;World Journal of Urology,2017